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ABSTRACT 
Objectives: In discussions of expanded measles control, elim- 
ination, and possible eradication, better estimates of disease 
burden are increasingly important to target vaccination control 
measures. Because global surveillance for measles is inade- 
quate, a model to quantify country-specific estimates of 
measles disease burden was formulated to help policy-makers 
consider control options. 
Methods: Country-specific demographics, developmental sta- 
tus, historic vaccine coverage rates, and age-specific vaccine 
efficacy and attack rates were used to determine the number 
of measles cases and deaths for 5year periods. 
Results: The model estimates an annual global incidence of 
32 million measles-susceptible persons (-25% of the global 
birth cohort), resulting in 28 million cases and 691 thousand 
deaths. Eighty-four percent (578,000) of the global deaths occur 
in the World Health Organization African and Southeast Asian 
regions. Twenty countries account for 82% of deaths attribut- 
able to measles, In nine countries, over 2% of the birth-cohort 
are estimated to die from measles. 
Conclusions: This methodology quantifies country- and age- 
specific measles disease burden and establishes regional and 
global disease patterns, allowing aggregations by income 
groups and regions, which aids policy formulation. The data 
may be continuously updated, based on dynamic changes in 
vaccine coverage rates and the incorporation of national vac- 
cination campaigns. 
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Measles is both endemic and epidemic throughout the 
world, and therefore, it is difficult to quantify global dis- 
ease burden at any one time. Although the World Health 
Organization (WHO) receives reports of measles disease 
from ministries of health through regional offices, these 
frequently represent an underestimation of the true inci- 
dence. As countries have variable reporting systems, there 
are no simple extrapolation techniques to quantify global 
disease burden. In discussions centered on expanded 
measles control, elimination, and possible eradication, bet- 
ter estimates of disease burden are increasingly impor- 
tant to focus and target vaccination control measures.’ 
Given the unreliable accuracy of reported measles 
cases, the WHO Expanded Programme for Immunizations 
(EPI) has used models to estimate disease burden. The 
WHO estimates the number of susceptible persons in 
each annual birth cohort as a function of measles vacci- 
nation rates and a differential vaccine efficacy based on 
age of administration. For each country, 80% of suscepti- 
ble persons are assumed to develop measles. For those 
countries that have adopted a campaign approach using 
pulse vaccination for measles control,2 1% of susceptible 
persons are assumed to develop measles (Olive JM. World 
Health Organization. Personal communication). Country- 
specific case fatality rates, ranging from 0.05% to 6% (EPI. 
Unpublished data) are then applied to the number of 
cases determined for each country, to estimate the num- 
ber of measles-related fatalities. The WHO model has the 
advantage of simplicity and routine historic use. 
However, with the introduction of mass campaigns 
of vaccination against measles and the sustained high 
coverage rates in many countries, the current EPI model 
does not adequately address many of the subtleties of 
measles transmission dynamics, such as age-specific attack 
rates and population immunity, that offer an extended 
herd effect at the local, national, regional, and global level.3 
With expanded efforts of measles control, reliable esti- 
mates of disease burden become increasingly important, 
to help guide policy planning and vaccine strategies. In 
this article a new methodology to quantify global measles 
disease burden is described that accounts for the age- 
distribution of measles susceptible persons, morbidity, 
and mortality, providing a framework for measles control 
14 
Global Measles Disease Burden / Miller 15 
efforts and economic assessments of various vaccination 
strategies. 
Table 2. Age-Specific Attack Rates of Susceptible 
Persons (Forces of Infection)* during Outbreak Periods 
Age Low income (%I High hcome (%) 
METHODS 
An epidemiologic model incorporating stochastic fea- 
tures, such as outbreak events, and compartmentalized 
by age-group and geographic features was formulated. 
The model incorporates country-specific population 
demographics, socioeconomic development status, his- 
toric coverage rates of measles vaccine (delivered rou- 
tinely or through periodic campaigns), age-specific 
vaccine efficacy, and forces of infection (Tables 1 and 2). 
It also includes a stochastic factor to indicate the likeli- 
hood of virus to enter a highly vaccinated population in 
a specific geographic area (e.g., island population or 
highly vaccinated regions, such as in select populations 
primarily in the Americas and Europe). 
Demographics 
For each country, age cohorts of children 0 to 6 months, 
7 to 12 months, 1 to 4 years, 5 to 9 years, 10 to 14 years, 
and 15 to 19 years of age are derived from United 
Nations-published country-specific birth rates adjusted 
by rates of infant mortality and under 5 mortality4,5 
Susceptibility 
Individuals in each successive birth-cohort are consid- 
ered immune for the first 6 months of life, based on 
maternal antibodies, after which they become susceptible 
6-12 mo 0.121 
I-4y 0.333 
5-9 y 0.345 
IO-14y 0.201 
15-19 y 0.144 
20-75~ 0.068 
*Adapted from Anderson RM, May RM.8 
0.121 
0.121 
0.345 
0.201 
0.144 
0.068 
(Figure 1). Individuals remain susceptible until they are 
successfully immunized or they develop disease, after 
which they remain immune for life. The number of sus- 
ceptible persons in each age cohort is dependent on his- 
toric vaccination coverage rates (including campaigns),6 
age-specific vaccine efficacy, and immunity from natural 
disease as estimated by previous iterations of the model 
(see Appendix A for formulae). 
Disease Incidence 
The measles basic reproductive rate (R,J indirectly deter- 
mines the threshold level of population immunity at 
which pathogen transmission continues to occur.’ When 
the proportion of the susceptible population exceeds the 
critical threshold of l/R, (approximately 6.7% for 
measles), the model predicts the occurrence of ongoing 
transmission. 
Country-specific outbreaks and endemic disease are 
assumed to occur whenever the critical susceptible 
Table 1. General Model Assumptions 
Parameter Data Source 
Population structure cohorts 
Country-specific United Nations Population Division4 UNICEF5 
Surviving birth cohort Surviving infants estimated using birth-rates adjusted for rates of infant mortality and <5 mortality 
1-4 years 
5-9 years 
IO-14 
15-20 
Vaccination coverage 
Country-specific Expanded Program on Immunization6 
Vaccine immunogenicity 
85% for vaccination at ~12 months Orenstein et ali5 
95% for vaccination at >I 2 months 
Force of infection 
See Table 2 Anderson and May,* Grenfell and Anderson,g Nokes and Andersoniosii 
Stochastic factor* 
Nonisland countries 0.00070 Reported incidence of estimated 1 - to 14.year-old susceptible persons from selected countries,+ 
Island countries 0.00008 following either campaigns or routine high coverage rates in excess of 95% 
Case:fatality rates 
Country-specific EPI. Unpublished data 
*Applied to those countries that effectively have continuously reduced population immunity in the l- to 14.year-old age group of less than l/R0 (~6.7%) either through 
routine coverage or with the implementation of campaign(s). 
+Countries include Argentina, Belize, Bolivia, Canada, Chile, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Peru, Uruguay, 
United States, Venezuela; Island countries include The Bahamas, Barbados, Cuba, Dominica, Grenada, Guyana, Haiti, Jamaica, Puerto Rico, Trinidad &Tobago. 
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Death from other cause 
Figure 1. Abbreviated schematic of determin- 
istic model of measles transmission incorpo- 
rating a vaccine-preventable strategy. Assuming 
all persons are susceptible to measles infec- 
tion 6 to 9 months after birth (postmaternal 
antibody protection), there are variable proba- 
bilities (letters A-D) for passage into other tran- 
sitional states throughout the lifetime of an 
individual. The variable probabilities are strati- 
fied geographically and by age and incorpo- 
rate overall population immunity. For each 
country, birth cohorts from the past 20 years 
are successively followed to account for the 
impact of national vaccination programs on cur- 
rent disease burden. A, vaccination coverage 
rate (age-specific and by dose); 5, vaccine effi- 
cacy by dose and timing of administration; C, 
age specific attack rate (varies by population 
density of susceptible persons); D, probabili- 
ties of progression to each outcome state. 
population exceeds 6.7%. Historically, during these out- 
break periods, an age-specific force of infection or attack 
rate in the susceptible population was applied leading 
to country-specific number of cases, deaths, and new 
immune persons to enter the next age cohort. In clas- 
sic deterministic models, forces of infection are derived 
by numerous population-specific parameters, including 
average age of infection and the lifetime probability of 
disease in the absence of vaccination.’ Attack rates of 
susceptible persons-forces of infection (see Table 2) 
for each country and age group were assumed on the 
basis of demographic structure and the historic control 
with vaccination as documented in previous studies.8-11 
Two sets of values were used, one for countries with a 
historic early-age onset of measles attributable to age 
structures predominately composed of children less 
than 15 years of age (most developing countries); the 
second for countries that traditionally have had a later 
onset of measles. 
For countries with estimated immunity in the l- to 
14-year-old age group of less than l/R0 (6.7%), measles 
outbreaks were assumed not to occur. However, in the 
absence of global eradication, measles cases could occur 
due to nonsustained transmission from imported cases. 
To account for these cases, stochastic factors were 
applied to simulate the chance infection of a susceptible 
person from imported virus. The stochastic factor was 
derived from the average reported number of cases as a 
percentage of the calculated susceptible population 1 to 
14 years of age from countries in the Americas that met 
the criteria of estimated population immunity of less than 
l& Because of the relative isolation of island nations, 
two stochastic factors were derived, one for island, and 
another for nonisland populations. For countries where 
outbreaks would not normally occur (population sus- 
ceptibility ~6.7%) the annual number of cases was esti- 
mated by multiplying the appropriate stochastic factor 
by the estimated susceptible population. 
RESULTS 
A susceptibility profile for each country was determined 
by the annual accumulation of measles susceptible per- 
sons aged 1 to 20 years (see Figure 1). Although the 
model estimates the percentage accumulation of sus- 
ceptible persons for each country, it does not predict the 
precise year when outbreaks will occur. However, in the 
absence of further control measures, it does estimate the 
number of cases and deaths that would occur on average 
over every 5-year period (assuming the maintenance of 
current levels of susceptible-person accumulation 
through vaccination and natural disease). These estimates 
are annualized by dividing by 5 and are aggregated by 
region (Figures 2 and 3) (Table 3). 
The model estimates a global annual incidence of 32 
million persons susceptible to measles, 67% in the WHO 
designated African (AFR) and Southeast Asia regions 
(SEAR), populations which account for 45% of the global 
infant cohort. Approximately 25% of each successive O- 
to 4-year-old global cohort remain susceptible to measles 
each year, owing to low vaccination rates and vaccine 
failures. By region, the accumulation of measles suscep- 
tible persons is most pronounced in AFR (54%) followed 
by the Eastern Mediterranean (31%) and SEAR (26%). This 
contrasts to the American region where only 5% of each 
successive 0- to 4-year-old cohort remains susceptible to 
measles, with the assumed current maintenance of peri- 
odic campaigns. 
Owing to the annual accumulation of susceptible 
persons, on average, an estimated 28 million cases of 
measles is expected each year. The global case distribu- 
tion is similar to that of the distribution of susceptible 
persons. Over 16 million (58%) cases are estimated to 
occur in SEAR and AFR regions. Given the higher case 
fatality rates for countries in these regions, 578 (84%) of 
the 69 1,000 estimated global measles deaths would occur 
in these two regions. 
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sP ‘ecific incident asles susceptible persons as 
’ Girth cohort ( 32.0 million susceptible persons) 
0% to 5% 
> 5% to 10% 
MO% to 25% 
S25% to 40% 
>40% 
Figure 2. Distribution of the annual incidence of measles-susceptible persons (shown as a percentage of the national birth cc 
distribution of cases by country (n = 27.6 million cases; .l dot = 200,000). 
short) and 
The 20 countries that contribute the most to measles 
mortality are listed in Table 4. These countries comprise 
59% of the global surviving birth cohort but account for 
82% of the average annual deaths due to measles. 
Although, most deaths are estimated to occur in India, the 
highest incidence occurs in Niger, Afghanistan, and Soma- 
lia. The model estimates that, in nine countries, over 2% 
of the birth cohort die from measles. A comparison of 
mortality rates in children under 5 years of age and rates 
of death attributable to measles for each country is 
included (see Table 4). Assuming that most deaths due to 
measles occur in children less than 5 years old, between 
5% and 10% of mortality in children under 5 years of age 
is attributable to measles in almost all of these countries. 
DISCUSSION 
Concern has been raised regarding the formulation of 
public health policy in the absence of adequate data.12 
Although global estimations of measles exist in the Global 
Burden of Disease study published in 1996,13 to date, the 
cited source of the methodology used to derive the esti- 
mates has yet to be published. Given the limitations of 
countries to adequately conduct surveillance for measles, 
this model allows one to quantify current disease bur- 
den attributable to measles and the expected impact of 
new control measures. Because this method character- 
izes the susceptible population by age groups, it also 
allows for specific estimates of cases and deaths that 
occur at different ages, thereby allowing for a quantifi- 
cation of the years of potential life lost and the disabil- 
ity-adjusted life years (DALY).‘* These metrics allow one 
to integrate age-specific morbidity and mortality for com- 
parisons to other diseases. Although age-specific case- 
fatality rates were not included, one might further 
elaborate this model as additional data become available. 
This model represents the next step of refinement in 
the setting of limited data to better quantify global dis- 
ease patterns. Further refinements may be possible, such 
as that which may be afforded by serosurveys of differ- 
ent countries to refine country- or region-specific forces 
of infection, to account for regional herd effects. However, 
the time and expense of such data collection must be 
weighed against the marginal advantages it would bring 
to current estimates. In addition, as better subnational 
data become available, the model can be modified to 
account for rural and urban population distributions, to 
more adequately reflect population-density transmission 
factors. However, until such data are available, this model 
can serve to estimate patterns of disease. 
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Figure 3. Distribution of estimated incidence of deaths attributable to measles by country. 
As new strategies for measles control are adopted, 
this model can serve to estimate the expected impact. 
By disaggregating each country by age-specific cohorts, 
it allows one to assess the impact of various targeting 
strategies over the course of time. As more regions 
increase their population immunity, stochastic factors 
play a more important role in disease transmission. 
Measles disease may then be predicted more by the 
chance presence of measles virus importation, deter- 
mined by national or regional and global levels of 
immunity. As immunity throughout the world increases, 
these contact rates of virus and susceptible persons 
decrease. The stochastic factors become the prime 
determinant of ongoing measles transmission over 
larger geographic areas. 
LIMITATIONS 
The model is limited mainly by the quality of the data that 
formulate it. Although, it offers a refinement over models 
based on global averages through its aggregation of coun- 
try-specific data, the data on which the assumptions are 
based may be flawed. Through the appropriate use of 
Table 3. Results: Population, Susceptible Persons, Susceptibility Profiles, Annual Range of Cases, and Deaths by WHO Regions 
WHO Region 
Surviving Estimated New 
Infants Measles-Susceptible 
I29 Million Persons Each Year* 
(100%) 32 Million (100%) 
Measles-Susceptible 
Persons as Percentage 
of Surviving Infants 
in Region (25%) 
Estimated Annual 
Cases to Occur 
1997-2001* 
(2 7.6 MU/ion) 
Estimated Annual 
Number of Deaths 
to Occur 1997-2001* 
(69 1.0 Thousand) 
Africa 22 (17) 12 (37) 54 7.3 351.3 
Americas 16 (12) 1 (2) 5 0.0 0.1 
Eastern Mediterranean 15 (12) 5 (14) 31 3.8 73.5 
Europe 11 (9) 2 (6) 18 2.2 8.6 
Southeast Asia 36 (28) 9 (30) 26 8.8 226.4 
Western Pacific 28 (22) 3 (11) 12 5.5 31.2 
*Assumes maintenance of current control measures. 
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Table 4. Top 20 Countries Accounting for the Most Deaths Due to Measles 
Country 
India 
Nigeria 
Ethiopia 
D.P.R. Congo 
Indonesia 
Pakistan 
Bangladesh 
Afghanistan 
Kenya 
Ivory Coast 
Ghana 
China 
Niger 
Vietnam 
Sudan 
Somalia 
Uganda 
Mali 
Surviving infants 
(Millions) 
24.0 
4.4 
2.2 
1.8 
4.4 
4.9 
3.7 
0.8 
1.1 
0.6 
0.6 
20.6 
0.4 
2.1 
1.0 
0.4 
0.9 
0.4 
Estimated Incidence Measles Death 
of Deaths Due to Measles Under 5 Mortality Rate* incidence 
(Thousands) (per 1000) (per 7000 <5-Year-Old Children) 
167 111 7 
96 191 22 
50 177 23 
33 207 18 
29 71 7 
26 136 5 
21 112 6 
20 257 26 
16 90 15 
13 150 21 
13 110 20 
11 47 1 
320 27 
::, 44 5 
IO 116 10 
10 211 24 
10 141 11 
9 220 21 
Tanzania 1.1 9 144 8 
Burkina Faso 0.4 8 158 19 
Total 75.8 569 8 
sensitivity analysis (adjusting assumptions through their 
range of uncertainty) this model can offer a range of val- 
ues for the outputs. 
The model provides disease burden estimates over 
5-year periods and cannot precisely predict ywhen out- 
breaks would occur. However, through the estimates of 
population levels of immunity, it indicates the likelihood 
of an outbreak to occur, when the percentage of sus- 
ceptible individuals in the population exceeds the epi- 
demic threshold of l&, approximately 6.7%. As such, it 
offers an accounting of how much disease can be pre- 
dicted over the course of several years but does not 
attempt to account for year-to-year variations. 
Deterministic models have several limitations. 
Although different sets of age-specific forces of infection 
were used based on historic patterns of transmission, 
they had been originally derived from “virgin” popula- 
tions, unexposed to measles. They also are based on a 
random mixing of cases and susceptible persons result- 
ing from a random distribution of coverage. This model 
only covers the age up through 20 years and does not 
account for rural and urban differences in transmission 
dynamics. The model has been formulated to allow addi- 
tional data input to account for these factors as data 
become more readily available, such as differential cov- 
erage rates for urban and rural populations. 
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Appendix A. Formulae for Estimations 
The model defines the number of susceptible persons in each country for any given year by the sum of the suscep- 
tible persons in each of the five age cohorts @us,) divided by the number of years or,> in that cohort: 
3 
sus, = ’ POP, - (CopPike$ + SUS~~~-~~&YI: 
i=. k=l 
Where: 
Sus, = country-specific measles-susceptible population. 
Cov = reported vaccination coverage rate in age cohort. 
Pop = population of cohort. 
eff = age-specific vaccine efficacy. 
A = force of infection per period. 
Y = number of years in cohort,. 
For each country and age cohort, the number of cases and deaths are defined by: 
6 Y 
Cases- = Sus,Ai Z/y 
i=Ok=l 
Deaths- = Cases,CFRx 
Where: 
2 = Stochastic factor (1 for countries where the percentage of susceptible persons 1-14 years of age within the pop- 
ulation exceeds l/R0 or 6.7%; for all other countries, 0.0007 and 0.00008 for nonisland and island countries, respec- 
tively). 
CFRx = country-specific case fatality rates. 
180 
sus,, = sus, 
.a=1 
180 
Cases,, = Casess 
a=1 
180 
Deaths,, = Deaths- 
x=1 
Global or regional aggregate data are determined by summing national totals of susceptible persons, cases, or deaths 
where x represents each national estimate of the 180 countries for which sufficient data exist. 
